{
    "clinical_study": {
        "@rank": "55400", 
        "arm_group": [
            {
                "arm_group_label": "metformin and L-citrulline", 
                "arm_group_type": "Experimental", 
                "description": "7.5 g L-citrulline p.o. and 750 mg metformin p.o. per day (3x 2.5 g, respectively 3x 250 mg) for 26 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "metformin placebo and L-citrulline placebo 3 times daily p.o. for 26 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to show that the intake of L-citrulline and metformin improves\n      muscle function and delay of progression in patients with Duchenne's muscular dystrophy."
        }, 
        "brief_title": "L-citrulline and Metformin in Duchenne's Muscular Dystrophy", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Duchenne's Muscular Dystrophy (DMD)", 
        "condition_browse": {
            "mesh_term": [
                "Muscular Dystrophy, Duchenne", 
                "Muscular Dystrophies"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a single center, randomized, double-blind, placebo controlled study. The study\n      medication consists of L-citrulline and metformin, respectively placebo given orally; 2.5 g\n      L-citrulline or placebo will be given 3 times daily, metformin containing 250 mg or placebo\n      will be administered 3 times daily. The duration of the study is 26 weeks and comprehends\n      one screening and three study visits."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Molecular diagnosis of DMD\n\n          -  Patients 7 - 10 years of age at time of screening\n\n          -  Ambulant\n\n          -  Ability to walk 150 m in the 6 min walking distance (6MWT)\n\n          -  D1 subdomain of the MFM scale >40%\n\n          -  stable treatment with steroids for >6 months or steroid na\u00efve patients\n\n        Exclusion Criteria:\n\n          -  Previous (3 months or less) or concomitant participation in another      therapeutic\n             trial\n\n          -  Use of L-citrulline, L-arginine or metformin within the last 3 months\n\n          -  Known individual hypersensitivity to L-citrulline or metformin\n\n          -  known or suspected malignancy\n\n          -  Other chronic disease or clinical relevant limitation of renal, liver, heart function\n             according to discretion of investigator\n\n          -  start of cortisone treatment or change in dosage <6 months prior to screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "10 Years", 
            "minimum_age": "7 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01995032", 
            "org_study_id": "DMD02"
        }, 
        "intervention": [
            {
                "arm_group_label": "metformin and L-citrulline", 
                "intervention_name": "750 mg metformin and 7.5 g L-citrulline daily p.o.", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Duchenne's muscular dystrophy", 
            "DMD"
        ], 
        "lastchanged_date": "November 26, 2013", 
        "location": {
            "contact": {
                "email": "ulrike.bonati@ukbb.ch", 
                "last_name": "Ulrike Bonati, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Basel", 
                    "country": "Switzerland", 
                    "state": "BS", 
                    "zip": "4031"
                }, 
                "name": "University Children's Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Dirk Fischer, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Ulrike Bonati, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "2", 
        "official_title": "\"A Double Blind Randomised Placebo Controlled Efficacy and Safety Study of L-citrulline and Metformin in Ambulant Children Aged Between 7 and 10 Years With Duchenne's Muscular Dystrophy\"", 
        "overall_contact": {
            "email": "ulrike.bonati@ukbb.ch", 
            "last_name": "Ulrike Bonati, MD", 
            "phone": "+41617042243"
        }, 
        "overall_contact_backup": {
            "email": "daniela.rubino@ukbb.ch", 
            "last_name": "Daniela Rubino"
        }, 
        "overall_official": {
            "affiliation": "University Children's Hospital Basel", 
            "last_name": "Dirk Fischer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean change of motor function measure (MFM) D1 subscore (assessing standing and transfers)", 
            "safety_issue": "No", 
            "time_frame": "baseline to week 26"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01995032"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean change of MFM total score, the D2, and D3 MFM subscores", 
                "safety_issue": "No", 
                "time_frame": "baseline to week 26"
            }, 
            {
                "measure": "Mean change of six minute walking distance (6MWD)", 
                "safety_issue": "No", 
                "time_frame": "baseline to week 26"
            }, 
            {
                "measure": "Change of quantitative muscle MRI (Magnetic Resonance Imaging) including muscle fat content (MFC) and T2 times of thigh muscles", 
                "safety_issue": "No", 
                "time_frame": "baseline to week 26"
            }, 
            {
                "measure": "Change in the plasma/urine concentration for markers of muscle necrosis, oxidative stress, nitrosative stress, and change of microRNA (miRNA)", 
                "safety_issue": "No", 
                "time_frame": "baseline to week 26"
            }, 
            {
                "measure": "Mean change of quantitative muscle force (QMT) of knee extension and elbow flexion using hand held dynamometry (HHD)", 
                "safety_issue": "No", 
                "time_frame": "baseline to week 26"
            }
        ], 
        "source": "University Hospital, Basel, Switzerland", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Basel, Switzerland", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}